- Gland Pharma has appointed Deepak Sapra as chief executive officer, with his appointment expected to take effect on November 16, 2026, subject to his acceptance of the offer.
- Sapra brings 27 years of executive experience, including more than 23 years in the pharmaceutical industry and experience across CDMO services, APIs, generics and global business development.
Gland Pharma has appointed Deepak Sapra as its new chief executive officer, with the company saying he will assume the role on November 16, 2026, subject to his acceptance of the offer. The appointment was approved by the company’s board following a recommendation from its Nomination and Remuneration Committee.
Sapra currently serves as CEO – API and Services at Dr Reddy’s Laboratories and is a board member of Aurigene Pharma Services. In his current role, he oversees global portfolio strategy and an integrated B2B business spanning generic pharmaceuticals, CDMO services, APIs, collaborations and alliances, public health and global patient access.
Sapra has 27 years of executive experience, including more than 23 years in the pharmaceutical industry. His experience covers business development, licensing, mergers and acquisitions, portfolio creation and market expansion across India, the US, Europe, Japan, Latin America, Africa and Asia-Pacific. He has also worked across CDMO partnerships, generics, APIs, sales and marketing, supply chain, R&D and operations.
Before his current position, Sapra served as CEO, Custom Pharmaceutical Services, where he led a global CDMO business serving innovator pharmaceutical companies in the US, Europe and Japan. Between 2011 and 2015, he held senior leadership positions in global generics business development and portfolio management.
Sapra holds a bachelor’s degree in mechanical engineering from the Indian Railways Institute of Mechanical and Electrical Engineering in Jamalpur and a master’s degree in management from IIM Bangalore. He has also been a Chevening Scholar at the University of Bradford and a Fulbright Fellow at Carnegie Mellon University.
